News - obinutuzumab

Filter

Current filters:

obinutuzumab

Popular Filters

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

Roche granted FDA Priority Review for obinutuzumab in the treatment of chronic lymphocytic leukemia

03-07-2013

Swiss drug major Roche (ROG: SIX) has announced today (July 3) that the US Food and Drug Administration…

obinutuzumabOncologypertuzumabPharmaceuticalRegulationRoche

Strong initial data on Genentech's obinutuzumab in most common blood cancer

16-05-2013

Genentech, the biotech subsidiary of Swiss drug major Roche Group (ROG: SIX), has announced positive…

BiotechnologyGA101GenentechobinutuzumabOncologyResearchRoche

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

04-02-2013

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…

BiotechnologyGA101MabTheraobinutuzumabOncologyPharmaceuticalResearchRituxanRoche

Chugai in co-development accord for obinutuzumab with Nippon Shinyaku

28-11-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

BiotechnologyChugai PharmaceuticalLicensingNippon ShinyakuobinutuzumabOncologyPharmaceuticalResearchrituximabRoche

Back to top